MetaVia (MTVA) Assets Average (2016 - 2026)
MetaVia's (MTVA) quarterly Assets Average came in at $12.9 million in Q4 2025, down 32.59% YoY from $19.2 million in Q4 2024, and down 22.08% on a QoQ basis from $16.6 million in Q3 2025.
MetaVia (MTVA) Assets Average (2016 - 2026) Analysis & Trends
MetaVia (MTVA) has 10 years of Assets Average data on file, last reported at $12.9 million in Q4 2025.
- Quarterly Assets Average fell 32.59% year-over-year to $12.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.9 million (down 32.59% YoY) and the FY2025 annual result came in at $13.7 million, down 29.86% from the prior year.
- Assets Average eased to $12.9 million in Q4 2025, from $16.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $32.5 million in Q1 2023 to a low of $8.8 million in Q3 2022.
- A 5-year average of $18.2 million and a median of $16.0 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average jumped 215.23% — and 2024, when it sank 38.79%.
- Tracing MTVA's Assets Average over 5 years: stood at $12.4 million in 2021, then jumped by 65.18% to $20.5 million in 2022, then rose by 19.75% to $24.6 million in 2023, then retreated by 21.95% to $19.2 million in 2024, then plunged by 32.59% to $12.9 million in 2025.
- The last three Assets Average figures came in at $12.9 million (Q4 2025), $16.6 million (Q3 2025), and $15.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 12.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.20 Mn |
| Dec 31, 2025 | 12.94 Mn |
| Sep 30, 2025 | 16.61 Mn |
| Jun 30, 2025 | 15.29 Mn |
| Mar 31, 2025 | 14.19 Mn |
| Dec 31, 2024 | 19.20 Mn |
| Sep 30, 2024 | 25.45 Mn |
| Jun 30, 2024 | 22.88 Mn |
| Mar 31, 2024 | 19.90 Mn |
| Dec 31, 2023 | 24.60 Mn |
| Sep 30, 2023 | 27.80 Mn |
| Jun 30, 2023 | 30.33 Mn |
| Mar 31, 2023 | 32.51 Mn |
| Dec 31, 2022 | 20.55 Mn |
| Sep 30, 2022 | 8.82 Mn |
| Jun 30, 2022 | 11.77 Mn |
| Mar 31, 2022 | 15.13 Mn |
| Dec 31, 2021 | 12.44 Mn |
| Sep 30, 2021 | 9.40 Mn |
| Jun 30, 2021 | 12.44 Mn |